Brandon M. Hall
YOU?
Author Swipe
View article: Table S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S10 shows gender-specificity of anti-ORF1p IgG titers among healthy subjects and cancer patients.
View article: Fig S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S9 shows comparison of anti-ORF1p IgG titers in cancer patients with or without exposure to anti‐cancer therapies.
View article: Table S6 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S6 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S6 shows results of logistic regression analysis of anti-ORF1 IgG titers in cancer patients relative to healthy individuals after adjusting for age.
View article: Table S4 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S4 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S4 shows the number of samples for five cancer types and distribution by disease stages.
View article: Table S8 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S8 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S8 shows the results of linear regression analysis: association between ORF1p IgG titers and individual cancer types (stages 1-2) relative to healthy subjects after adjustment for age.
View article: Fig S11 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S11 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S11 shows comparison of anti‐ORF1p, anti‐ORF2p and anti‐p53 IgG in blood samples from patients with SLE and healthy individuals.
View article: Table S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S9 shows comparison of anti-ORF1p IgG titers among healthy subjects of different races.
View article: Supplementary Methods from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Supplementary Methods from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Methods include synthesis and purification of recombinant L1 antigens, immunoassays for L1 antigens and peptides derived from ORF1p and ORF2p,and Western immunoblotting protocols
View article: Fig S11 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S11 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S11 shows comparison of anti‐ORF1p, anti‐ORF2p and anti‐p53 IgG in blood samples from patients with SLE and healthy individuals.
View article: Fig S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S3 shows immunofluorescent staining and Western immunoblotting of lysates of HeLa cells with inducible L1 expression.
View article: Fig S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S10 shows results of longitudinal study of anti‐ORF1p IgG titers in serum samples from healthy subjects.
View article: Fig S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S7 shows the ROC curves indicating specificity and sensitivity of anti‐ORF1p immunoassay for 5 cancer types.
View article: Data from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Data from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Long interspersed nuclear element-1 (LINE-1 or L1), the most abundant family of autonomous retrotransposons occupying over 17% of human DNA, is epigenetically silenced in normal tissues by the mechanisms involving p53 but is frequently der…
View article: Table S11 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S11 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S11 shows comparison of anti-ORF1p IgG titers between indicated groups of subjects.
View article: Supplementary Methods from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Supplementary Methods from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Methods include synthesis and purification of recombinant L1 antigens, immunoassays for L1 antigens and peptides derived from ORF1p and ORF2p,and Western immunoblotting protocols
View article: Table S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S10 shows gender-specificity of anti-ORF1p IgG titers among healthy subjects and cancer patients.
View article: Figure S2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Figure S2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S2 shows anti‐ORF1p, anti‐ORF2p IgG titers and anti‐p53 IgG signals in serum samples of patients with 14 cancer types and healthy individuals.
View article: Fig S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S7 shows the ROC curves indicating specificity and sensitivity of anti‐ORF1p immunoassay for 5 cancer types.
View article: Table S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S1 contains the list of synthetic peptides derived from ORF1p.
View article: FIGURE 1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
FIGURE 1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Approach and proof of concept. A, Hypotheses: proteins encoded by L1 are expected to be recognized as tumor-associated antigens and become targets for antibody response. This response is stimulated by the cGAS-STING-mediated inducti…
View article: Table S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S7 shows the results of linear regression analysis of association between ORF1p IgG titers and individual cancer types relative to healthy subjects after adjustment for age.
View article: Fig S5 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S5 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S5 shows anti‐ORF2p IgG titers in the blood of esophageal, lung, pancreatic, ovarian and liver cancer patients.
View article: Table S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S3 shows IgG titers against ORF1p-derived peptides in healthy persons, lung, and ovarian cancer patients.
View article: Fig S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S10 shows results of longitudinal study of anti‐ORF1p IgG titers in serum samples from healthy subjects.
View article: Table S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S1 contains the list of synthetic peptides derived from ORF1p.
View article: Table S11 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Table S11 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Table S11 shows comparison of anti-ORF1p IgG titers between indicated groups of subjects.
View article: Fig S8 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S8 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S8 shows comparison of anti‐ORF1p IgG titers cancer patients with different tobacco smoking history.
View article: Fig S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S3 shows immunofluorescent staining and Western immunoblotting of lysates of HeLa cells with inducible L1 expression.
View article: Figure S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Figure S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S1 shows characteristics of HeLa cells with tetracycline-inducible L1 retrotransposition reporter.
View article: Fig S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Fig S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans Open
Supplementary Figure S9 shows comparison of anti-ORF1p IgG titers in cancer patients with or without exposure to anti‐cancer therapies.